

LIVERACE™ COMBO · PRODUCT OVERVIEW

Multi-Omic. Single Well.

Two biomarkers. One reaction well. miR-122 + CK-18 detected simultaneously for complete early-to-confirmed liver toxicity profiling across preclinical and clinical studies.



LiverAce™ COMBO

MIR-122 & CK-18

Dual Biomarker

Multi-Omics

Cross-Species

- **Two biomarkers. One well. One platform.** miR-122 captures early hepatocellular stress while CK-18 confirms apoptotic injury. Simultaneous dual detection from a single 25 µL sample, no multiplexing complexity.
- **Multi-Omic liver toxicity profiling.** Comprehensive assessment combining miRNA and protein biomarkers in a single reaction, delivering the complete injury picture that PCR-free chemistry uniquely enables.
- **FDA Letter of Support.** Both miR-122 and CK-18 qualified via the IMI TransBioLine Consortium. The only PCR-free dual assay aligned with these regulatory scientific findings.

FOR RESEARCH USE ONLY · NOT FOR DIAGNOSTIC PROCEDURES

www.destinagenomics.com · info@destinagenomics.com

Av. de la Innovación 1, Office 112 · 18016 Granada, Spain

© 2026 Destina Genomica S.L.



LEARN MORE

PRODUCT

For Pharma & CROs

LiverAce™ COMBO

Multi-Omic. Single Well.

For comprehensive liver toxicity monitoring, LiverAce™ COMBO detects miR-122 and CK-18 simultaneously in a single well. miR-122 for early hepatocellular stress and CK-18 for confirmed apoptotic injury. The **multi-omic approach** delivers complete liver toxicity profiling in one assay.



Multi-Omic approach using **immunoassay workflows** and platforms

THE CHALLENGE · LIVER TOXICITY IN DRUG DEVELOPMENT

\$3B

AVG. COST PER APPROVED DRUG

#1

CAUSE OF DRUG WITHDRAWAL

750+

DRUGS LINKED TO LIVER TOXICITY

10M+


PATIENTS AFFECTED/YEAR

KEY FEATURES




Dual Biomarker

miR-122 + CK-18 in one reaction well



Early + Confirmed

Onset detection & injury confirmation



Luminex Ready

No capital investment needed



Multi-Omics

miRNA + protein biomarkers in one assay



25 µL Sample

Minimal blood volume for animal models



Cross-Species

Preclinical → Clinical

BIOMARKER DETECTION



REGULATORY VALIDATION

- ✓ FDA Letter of Support for miR-122 — IMI TransBioLine Consortium research
- ✓ miR-122 & CK-18 endorsed by EMA & FDA — qualified via IMI TransBioLine
- ✓ Only commercial single-well PCR-free dual assay matching consortium scientific findings

COMPLETE DRUG DEVELOPMENT PROCESS — ONE ASSAY

PRE-CLINICAL

CLINICAL

In Vitro
Organoids

In Vivo
Animal Species

Clinical
Phase I → III

Same assay · Same sample type · Cross-species biomarker conservation

